Lilly's triple-G agonist shows unique promise in late-stage diabetes trial
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A late-stage trial for a diabetes treatment has shown promise. The treatment in question is a triple-G agonist developed by Lilly. The trial results indicate the treatment has unique potential.